Canaccord Genuity Group restated their buy rating on shares of Phreesia (NYSE:PHR – Free Report) in a research note issued to investors on Friday, Benzinga reports. They currently have a $46.00 target price on the stock. A number of other research firms have also issued reports on PHR. Stephens reaffirmed an overweight rating and set […]
Phreesia (NYSE:PHR – Get Free Report) and Edgio (NASDAQ:EGIO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability. Insider & Institutional Ownership 93.1% of Phreesia shares are […]
Brown Advisory Inc. increased its position in shares of Phreesia, Inc. (NYSE:PHR – Free Report) by 4.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,227,530 shares of the company’s stock after purchasing an additional 130,622 shares during the quarter. Brown Advisory Inc. […]
Envestnet Asset Management Inc. grew its stake in Phreesia, Inc. (NYSE:PHR – Free Report) by 9.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,263 shares of the company’s stock after purchasing an additional 1,438 shares during the period. Envestnet Asset Management […]
Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP Michael J. Davidoff sold 1,075 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $31.75, for a total value of $34,131.25. Following the transaction, the senior vice president now owns 93,576 shares of the company’s […]